Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction notice to "Ameliorative potential of sitagliptin and/or resveratrol on experimentally-induced clear cell renal cell carcinoma" [Biomed. Pharmacother. 97 (2017) 667-674.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2023
Same author

Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer's Disease in Rats.

Pharmaceuticals (Basel, Switzerland)·2023
Same author

Perindopril/Ambrosin Combination Mitigates Dextran Sulfate Sodium-Induced Colitis in Mice: Crosstalk between Toll-Like Receptor 4, the Pro-Inflammatory Pathways, and SIRT1/PPAR-γ Signaling.

Pharmaceuticals (Basel, Switzerland)·2022
Same author

Omarigliptin/galangin combination mitigates lipopolysaccharide-induced neuroinflammation in rats: Involvement of glucagon-like peptide-1, toll-like receptor-4, apoptosis and Akt/GSK-3β signaling.

Life sciences·2022
Same author

Immune checkpoint proteins (PD-L1 and CTLA-4) in endometrial carcinoma: prognostic role and correlation with CD4<sup>+</sup>/CD8<sup>+</sup> tumor infiltrating lymphocytes (TILs) ratio.

Journal of immunoassay & immunochemistry·2021
Same author

The Role of Stem Cell Factor in Hyperpigmented Skin Lesions.

Asian Pacific journal of cancer prevention : APJCP·2019

Related Experiment Video

Updated: May 28, 2026

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software
07:32

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

CD155 Expression in Invasive Breast Carcinoma: Association with Immune Tumor Microenvironment.

Asmaa Abdelkerim1, Fatma Mohamed Khairy Ibrahim1, Radwa Oreby1

  • 1Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.

Iranian Journal of Pathology
|May 27, 2026
PubMed
Summary

CD155, a key immune checkpoint molecule, is linked to aggressive invasive breast carcinoma (IBC) features. Its expression correlates with tumor-infiltrating NK cells and TAMs, suggesting a role in IBC progression.

Keywords:
CD155CD163CD56breast carcinomatumor associated macrophagestumor infiltrating natural killer cells

More Related Videos

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Related Experiment Videos

Last Updated: May 28, 2026

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software
07:32

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Area of Science:

  • Immunology
  • Oncology
  • Pathology

Background:

  • CD155 functions as an immune checkpoint molecule interacting with T-lymphocytes and NK cells within the tumor microenvironment (TME).
  • NK cells and tumor-associated macrophages (TAMs) are critical immune components within the TME.

Purpose of the Study:

  • To investigate the expression of CD155 and its relationship with NK cells (CD56) and TAMs (CD163) in invasive breast carcinoma (IBC).
  • To determine the association of CD155, NK cells, and TAMs with clinicopathological features and molecular subtypes of IBC.

Main Methods:

  • Immunohistochemical analysis of CD155, CD56, and CD163 expression in 85 cases of invasive breast carcinoma (IBC).

Main Results:

  • CD155 positivity (52.9%) was significantly associated with larger tumor size, higher grade, advanced stage, lymphovascular invasion (LVI), and aggressive molecular subtypes.
  • High densities of tumor-infiltrating NK cells (30.6%) and stromal TAMs (55.3%) were also linked to aggressive IBC features.
  • CD155 expression showed a significant correlation with the densities of NK cells and TAMs in the TME.

Conclusions:

  • CD155 expression, along with high densities of NK cells and TAMs, contributes to the progression of invasive breast carcinoma.
  • CD155 plays a significant immunoregulatory role within the tumor microenvironment of IBC.